Association of antidepressants plus antithrombotics and bleeding risk: a pharmacovigilance study.
Eur J Clin Pharmacol
; 80(2): 283-285, 2024 Feb.
Article
em En
| MEDLINE
| ID: mdl-38112734
ABSTRACT
AIM:
The present study investigated the risk of bleeding when antidepressants are added to antithrombotics.METHODS:
Using data registered in VigiBase®, the WHO pharmacovigilance database, between 01/01/2000 and 31/12/2022, we compared the risk of reporting "serious" bleeding (Reporting Odds Ratio, ROR) with antidepressants + antithrombotics versus antithrombotics alone.RESULTS:
Increased values of ROR were found for the association Serotonin Reuptake Inhibitors (SRIs) + Direct Oral Anticoagulants (DOACs) versus DOACs alone (ROR=1.49(1.17-1.89)). Similar results were found for Factor Xa inhibitors or Thrombin inhibitors. This association was also found for other antithrombotics Vitamin K Antagonists (ROR=1.37(1.12-1.68)), Platelet Aggregation Inhibitors PAIs (ROR=1.38(1.21-1.57)) and Heparins (2.04(1.59-2.62)) but not with other antidepressants (Non-Selective Monoamine Reuptake Inhibitors, NSMRIs).CONCLUSION:
The present study suggests an increased risk of "serious" bleeding when SRIs (but not NSMRIs) are associated with antithrombotics (all antithrombotics and not only DOACs).Palavras-chave
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Farmacovigilância
/
Fibrinolíticos
Limite:
Humans
Idioma:
En
Revista:
Eur J Clin Pharmacol
Ano de publicação:
2024
Tipo de documento:
Article